Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
Last week, we reported on a study published in The Lancet that examined the safety and efficacy of a judicious short course of an opioid analgesic for acute low back pain (LBP) and neck pain in adults aged ≥18 years.
The study
Between February 2016 and March 2022, investigators recruited 347 individuals who presented at one of 157 primary care or emergency department sites in Australia with ≤12 weeks of LBP or neck pain (or both) of at least moderate intensity. Participants were randomly assigned to receive guideline-recommended care plus either an opioid (n=174) or placebo (n=173) for up to 6 weeks. Participants in the opioid group received up to 20 mg of modified-release oxycodone-naloxone per day orally.
The findings
Results showed no significant difference in pain scores at 6 weeks between the 2 cohorts, with a score of 2.78 in the opioid group and 2.25 in the placebo group.
Pain severity was not significantly different between groups at week 12, however, the between-group difference increased over time and by week 52 there was a small difference favoring placebo, according to researchers.
In addition, 35% of participants in the opioid group and 30% of those in the placebo group reported non-serious adverse events. The most common adverse events reported across both groups were nausea and vomiting, constipation, headache, dizziness, and somnolence.
A note from authors
"Opioids should not be recommended for acute non-specific low back pain or neck pain given that we found no significant difference in pain severity compared with placebo. This finding calls for a change in the frequent use of opioids for these conditions."
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Christoph Correll, MD, discusses the new once-monthly olanzapine injection for schizophrenia, including clinical efficacy, metabolic risks, and patient selection.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.